Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.

Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, Saba NF, Pakkala S, Patel PR, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M, Higgins KA.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30156-1. doi: 10.1016/j.cllc.2019.06.014. [Epub ahead of print]

PMID:
31296433
2.

A Phase I Pharmacokinetic Study of Belinostat in Patients with Advanced Cancers and Varying Degrees of Liver Dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Jul 4. doi: 10.1111/bcp.14054. [Epub ahead of print]

PMID:
31271459
3.

EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.

Rice SJ, Liu X, Wang HG, Belani CP.

PLoS One. 2019 May 31;14(5):e0217657. doi: 10.1371/journal.pone.0217657. eCollection 2019.

4.

Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling.

Rice SJ, Liu X, Zhang J, Jia B, Zheng H, Belani CP.

Lung Cancer. 2019 May;131:58-61. doi: 10.1016/j.lungcan.2019.03.014. Epub 2019 Mar 18.

PMID:
31027698
5.

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN Jr.

Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

6.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
7.

Absolute Quantification of All Identified Plasma Proteins from SWATH Data for Biomarker Discovery.

Rice SJ, Liu X, Zhang J, Belani CP.

Proteomics. 2019 Feb;19(3):e1800135. doi: 10.1002/pmic.201800135. Epub 2019 Jan 18.

PMID:
30585401
8.

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.

Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1.

PMID:
30513377
9.

Membrane trafficking and exocytosis are upregulated in port wine stain blood vessels.

Yin R, Rice SJ, Wang J, Gao L, Tsai J, Anvari RT, Zhou F, Liu X, Wang G, Tang Y, Mihm MC Jr, Belani CP, Chen DB, Nelson JS, Tan W.

Histol Histopathol. 2019 May;34(5):479-490. doi: 10.14670/HH-18-051. Epub 2018 Oct 10.

PMID:
30302745
10.

Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.

Zhang L, Belani CP, Zhang PH, Wang X, Yang L, Orlando M, Wu YL.

Lung Cancer. 2018 Jan;115:121-126. doi: 10.1016/j.lungcan.2017.11.026. Epub 2017 Nov 28.

PMID:
29290253
11.

Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes.

Wan Y, Cheng G, Liu X, Hao SJ, Nisic M, Zhu CD, Xia YQ, Li WQ, Wang ZG, Zhang WL, Rice SJ, Sebastian A, Albert I, Belani CP, Zheng SY.

Nat Biomed Eng. 2017;1. pii: 0058. doi: 10.1038/s41551-017-0058. Epub 2017 Apr 10.

12.

Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients.

Dougall AL, Swanson J, Kyutoku Y, Belani CP, Baum A.

J Appl Biobehav Res. 2017 Sep;22(3). pii: e12065. doi: 10.1111/jabr.12065. Epub 2017 Apr 18.

13.

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS.

Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.

14.

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2.

15.

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.

Higgins KA, O'Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, Patel KR, Patel PR, Robinson CG, Simone CB 2nd, Owonikoko TK, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):128-137. doi: 10.1016/j.ijrobp.2016.10.001. Epub 2016 Oct 11.

16.

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.

Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS.

JAMA Oncol. 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280. Review.

PMID:
27978552
17.

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

Belani CP, Chakraborty BC, Modi RI, Khamar BM.

Ann Oncol. 2017 Feb 1;28(2):298-304. doi: 10.1093/annonc/mdw608.

PMID:
27831503
18.

Pulmonary Rehabilitation in Lung Cancer.

Wang H, Liu X, Rice SJ, Belani CP.

PM R. 2016 Oct;8(10):990-996. doi: 10.1016/j.pmrj.2016.03.010. Epub 2016 Apr 6. Review.

PMID:
27060645
19.

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, Menander KB, Belani CP.

Clin Lung Cancer. 2016 May;17(3):169-76. doi: 10.1016/j.cllc.2016.02.003. Epub 2016 Feb 19.

20.

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.

Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP.

Oncotarget. 2016 Aug 30;7(35):56233-56240. doi: 10.18632/oncotarget.9316.

21.

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.

22.

A patient with complex multiple genomic ALK alterations.

Liu X, Rice SJ, Jamis-Dow CA, Abendroth C, Ali S, Almokadem S, Belani CP.

Thorax. 2016 Apr;71(4):383-5. doi: 10.1136/thoraxjnl-2015-207950. Epub 2016 Feb 2. No abstract available.

PMID:
26839360
23.

Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.

Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, Saba NF, Belani CP, Khuri FR, Ramalingam SS, Owonikoko TK.

Cancer. 2016 Jan 1;122(1):50-60. doi: 10.1002/cncr.29674. Epub 2015 Oct 6.

24.

Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.

Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2015 Aug;10(8):1142-7. doi: 10.1097/JTO.0000000000000572. Review.

25.

Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.

Rice SJ, Miller B, Wagman M, Jamorabo DS, Liu X, Belani CP.

Curr Mol Pharmacol. 2016;9(3):183-195. Review.

PMID:
26177648
26.

Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).

Liu X, Belani CP.

Curr Mol Pharmacol. 2016;9(3):182. No abstract available.

PMID:
26177639
27.

Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung.

Rice SJ, Liu X, Miller B, Joshi M, Zhu J, Caruso C, Gilbert C, Toth J, Reed M, Rassaei N, Das A, Barochia A, El-Bayoumy K, Belani CP.

Proteomics. 2015 Sep;15(18):3267-77. doi: 10.1002/pmic.201500029. Epub 2015 Jul 3.

PMID:
26058877
28.

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS.

Lung Cancer. 2015 Jul;89(1):66-70. doi: 10.1016/j.lungcan.2015.04.015. Epub 2015 May 8.

29.

Afatinib for the treatment of metastatic non-small cell lung cancer.

Joshi M, Rizvi SM, Belani CP.

Cancer Manag Res. 2015 Feb 19;7:75-82. doi: 10.2147/CMAR.S51808. eCollection 2015. Review.

30.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

Joshi M, Rice SJ, Liu X, Miller B, Belani CP.

PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210. eCollection 2015.

31.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

32.

Complex chronic conditions in Rhode Island's pediatric populace: implications for palliative and hospice services, 2000-2012.

Jamorabo DS, Belani CP, Martin EW.

J Palliat Med. 2015 Apr;18(4):350-7. doi: 10.1089/jpm.2014.0226. Epub 2014 Dec 18.

PMID:
25522161
33.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

34.

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.

Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP.

Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10. doi: 10.1007/s00280-014-2488-7. Epub 2014 Jun 8.

PMID:
24908435
35.

Targeted immunotherapy for non-small cell lung cancer.

Vasekar M, Liu X, Zheng H, Belani CP.

World J Clin Oncol. 2014 May 10;5(2):39-47. doi: 10.5306/wjco.v5.i2.39. Review.

36.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.

Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV.

BMC Cancer. 2014 Apr 25;14:290. doi: 10.1186/1471-2407-14-290.

37.

Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?

Varlotto JM, Decamp MM, Flickinger JC, Lake J, Recht A, Belani CP, Reed MF, Toth JW, Mackley HB, Sciamanna CN, Lipton A, Ali SM, Mahraj RP, Gilbert CR, Yao N.

Front Oncol. 2014 Mar 7;4:37. doi: 10.3389/fonc.2014.00037. eCollection 2014.

38.

Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, Ren X.

Cancer Biol Ther. 2014 May;15(5):570-7. doi: 10.4161/cbt.28162. Epub 2014 Feb 20.

39.

Taxanes, past, present, and future impact on non-small cell lung cancer.

Joshi M, Liu X, Belani CP.

Anticancer Drugs. 2014 May;25(5):571-83. doi: 10.1097/CAD.0000000000000080. Review.

PMID:
24463482
40.

Endobronchial valve placement for spontaneous pneumothorax from stage IIIA non-small cell lung cancer facilitates neoadjuvant therapy.

Gilbert CR, Toth JW, Kaifi JT, Belani CP, Varlotto J, Reed MF.

Ann Thorac Surg. 2013 Dec;96(6):2225-7. doi: 10.1016/j.athoracsur.2013.04.119.

PMID:
24296192
41.

Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells.

Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY.

Clin Chem. 2014 Feb;60(2):323-33. doi: 10.1373/clinchem.2013.206805. Epub 2013 Oct 16.

42.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.

Lung Cancer. 2013 Sep;81(3):416-21. doi: 10.1016/j.lungcan.2013.06.002. Epub 2013 Jul 10.

PMID:
23849982
43.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ.

Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.

44.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

45.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

46.

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

Obasaju C, Bowman L, Wang P, Shen W, Winfree KB, Smyth EN, Boye ME, John W, Brodowicz T, Belani CP.

Ann Oncol. 2013 Jun;24(6):1534-42. doi: 10.1093/annonc/mdt123. Epub 2013 Apr 4.

47.

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.

Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3.

48.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.

Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Adjei AA, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA.

Cancer Chemother Pharmacol. 2013 May;71(5):1273-85. doi: 10.1007/s00280-013-2126-9. Epub 2013 Mar 7.

PMID:
23468081
49.

Small-cell lung cancer: an update on targeted therapies.

Joshi M, Ayoola A, Belani CP.

Adv Exp Med Biol. 2013;779:385-404. doi: 10.1007/978-1-4614-6176-0_18. Review.

PMID:
23288650
50.

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.

Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC.

Int J Nanomedicine. 2012;7:5555-64. doi: 10.2147/IJN.S35751. Epub 2012 Oct 19.

Supplemental Content

Loading ...
Support Center